PDCD1 and non-small cell lung carcinoma: In routine practice, intensifying immune activation with dual checkpoint blockade (e.g., CTLA-4 plus PD-1) increases the rates and grades of immune-related adverse events and does not consistently outperform PD-1 monotherapy for overall survival across NSCLC settings; benefits remain program- and subgroup-specific (131).